id	title	authors_short	authors_full	year	journal	volume	issue	pages	url	doiEASL_2017_FRI_205	Pooled resistance analysis in HCV genotype 1–6-infected patients treated with glecaprevir/pibrentasvir in phase 2 and 3 clinical trials	Krishnan et al.	P. Krishnan, G. Schnell, R. Tripathi, T. Ng, T. Reisch, J. Beyer, T. Dekhtyar, M. Irvin, W. Xie, L. Larsen, F. Mensa, T. Pilot-Matias and C. Collins	2017	J. Hepatol.	66	1	S500	https://www.journal-of-hepatology.eu/article/S0168-8278(17)31399-5/fulltext	https://doi.org/10.1016/S0168-8278(17)31399-5EASL_2013_Poster_1191	GS-5816, A SECOND GENERATION HCV NS5A INHIBITOR WITH POTENT ANTIVIRAL ACTIVITY, BROAD GENOTYPIC COVERAGE AND A HIGH RESISTANCE BARRIER	Cheng et al.	G. Cheng, M. Yu, B. Peng, Y.-J. Lee, A. Trejo-Martin, R. Gong, C. Bush, A. Worth, M. Nash, K. Chan, H. Yang, R. Beran, Y. Tian, J. Perry, J. Taylor, C. Yang, M. Paulson, W. Delaney and J.O. Link	2013	J. Hepatol.	58	Supplement 1	S484-S485	https://www.journal-of-hepatology.eu/article/S0168-8278(13)61192-7/pdf	https://doi.org/10.1016/S0168-8278(13)61192-7Pooled_phase_III_EASL_2017_Abs_248	No impact of RASs on the high efficacy of SOF/VEL/VOX for 12 weeks in DAA-experienced patients: an integrated resistance analysis of the POLARIS-1 and POLARIS-4 studies	Sarrazin et al.	C. Sarrazin, C.L. Cooper, M.P. Manns, R.K. Reddy, K. Kowdley, H. Dvory-Sobol, E. Svarovskia, R. Martin, B.P. Doehle, G. Camus, L.M. Stamm, R.H. Hyland, D.M. Brainard, H. Mo, S.C. Gordon, M. Bourlière, S. Zeuzem and S.L. Flamm	2017	J. Hepatol.	66	1	S299	https://www.journal-of-hepatology.eu/article/S0168-8278(17)30915-7/pdf	https://doi.org/10.1016/S0168-8278(17)30915-7EASL_2017_Abs_THU-257	No impact of RASs on the high efficacy of SOF/VEL/VOX for 8 weeks in DAA-naïve patients: an integrated resistance analysis of the POLARIS-2 and POLARIS-3 studies	Wyles, et al.	D. Wyles, A. Thompson, E. Lawitz, B. Willems, E.J. Gane, E. Svarovskaia, H. Dvory-Sobol, R. Martin, G. Camus, B.P. Doehle, L.M. Stamm, R.H. Hyland, D.M. Brainard, H.M. Mo, T. Asselah, I. Jacobson, G.R. Foster and S. Roberts	2017	J. Hepatol.	66	1	S303	https://www.journal-of-hepatology.eu/article/S0168-8278(17)30924-8/pdf	https://doi.org/10.1016/S0168-8278(17)30924-8AASLD_2016_Abs_846	Integrated Resistance Analyses of HCV-infected Patients treated with Sofosbuvir, Velpatasvir and Voxilaprevir for 8 and 12 weeks from Phase 2 Studies	Reau, et al.	N. Reau, M. H. Nguyen, K. V. Kowdley, E.  J. Gane, H. Dvory-Sobol, E. S. Svarovskaia, J. C. Yang, L. M. Stamm, D. M. Brainard, M. D. Miller, H. Mo, E. Lawitz, P. Y. Kwo, M. P. Curry and I. M. Jacobson	2016	Hepatology	64	1	415A-416A	https://aasldpubs.onlinelibrary.wiley.com/doi/epdf/10.1002/hep.28798	AASLD_2017_Abs_1176	Susceptibility to Voxilaprevir of NS3 Resistance-Associated Substitutions and of Clinical Isolates from Direct Acting Antiviral-Experienced and-Naive Patients	Dvory-Sobol et al.	H. Dvory-Sobol, B. Han, J. Lu, B. Parhy, D. Hsieh, E. Zhou, M. Bourlière, I. Jacobson, L. M. Stamm, G. Camus, R. Martin, E. S. Svarovskaia and H. Mo	2017	Hepatology	66	S1	632A	https://onlinelibrary.wiley.com/doi/full/10.1002/hep.29501	https://doi.org/10.1002/hep.29501AASLD_2015_Abs_718	Characterization of HCV Resistance from a 3-Day Monotherapy Study of GS-9857, a Novel Pangenotypic NS3/4A Protease Inhibitor	Lawitz et al.	E. Lawitz, H. Dvory-Sobol, J. C. Yang, L. M. Stamm, J. Taylor, D. M. Brainard, M. D. Miller, H. Mo and M. Rodriguez-Torres	2015	Hepatology	62	1	566A	https://www.aasld.org/sites/default/files/2015SupplementFULLTEXT.pdf	30125371	Frequent Antiviral Treatment Failures in Patients Infected With Hepatitis C Virus Genotype 4, Subtype 4r.	Fourati et al.	S. Fourati, C. Rodriguez, C. Hézode, A. Soulier, I. Ruiz, L. Poiteau, S. Chevaliez and J. M. Pawlotsky	2019	Hepatology	69	2	513-523		https://doi.org/10.1002/hep.3022530107485	High Cure Rates With Grazoprevir-Elbasvir With or Without Ribavirin Guided by Genotypic Resistance Testing Among Human Immunodeficiency Virus/Hepatitis C Virus-coinfected Men Who Have Sex With Men.	Braun et al.	D. L. Braun, B. Hampel, R. Kouyos, H. Nguyen, C. Shah, M. Flepp, M. Stöckle, A. Conen, C. Béguelin, P. Künzler-Heule, D. Nicca, P. Schmid, J. Delaloye, M. Rougemont, E. Bernasconi, A. Rauch, H. F. Günthard, J. Böni, J. S. Fehr and Swiss HIV Cohort Study 	2019	Clin. Infect. Dis.	68	4	569-576		https://doi.org/10.1093/cid/ciy54729599611	Daclatasvir plus asunaprevir in treatment-naïve patients with hepatitis C virus genotype 1b infection.	Wei et al.	L. Wei, F. S. Wang, M. X. Zhang, J. D. Jia, A. A. Yakovlev, W. Xie, E. Burnevich, J. Q. Niu, Y. J. Jung, X. J. Jiang, M. Xu, X. Y. Chen, Q. Xie, J. Li, J. L. Hou, H. Tang, X. G. Dou, Y. Gandhi, W. H. Hu, F. McPhee, S. Noviello, M. Treitel, L. Mo and J. Deng	2018	World J. Gastroenterol.	24	12	1361-1372		https://doi.org/10.3748/wjg.v24.i12.136129504692	Efficacy of ledipasvir/sofosbuvir with or without ribavirin for 12 weeks in genotype 1b HCV patients previously treated with a nonstructural protein 5A inhibitor-containing regimen.	Ikeda et al.	H. Ikeda, T. Watanabe, H. Shimizu, T. Hiraishi, R. Kaneko, T. Baba, H. Takahashi, K. Matsunaga, N. Matsumoto, H. Yasuda, C. Okuse, S. Iwabuchi, M. Suzuki and F. Itoh	2018	Hepatol. Res.	48	10	802-809		https://doi.org/10.1111/hepr.1307429473975	Elbasvir/grazoprevir and sofosbuvir for hepatitis C virus genotype 3 infection with compensated cirrhosis: A randomized trial.	Foster et al.	G. R. Foster, K. Agarwal, M. E. Cramp, S. Moreea, S. Barclay, J. Collier, A. S. Brown, S. D. Ryder, A. Ustianowski, D. M. Forton, R. Fox, F. Gordon, W. M. Rosenberg, D. J. Mutimer, J. Du, C. L. Gilbert, E. Asante-Appiah, J. Wahl, M. N. Robertson, E. Barr and B. Haber	2018	Hepatology	67	6	2113-2126		https://doi.org/10.1002/hep.2985229461687	Efficacy of elbasvir and grazoprevir in participants with hepatitis C virus genotype 4 infection: A pooled analysis.	Asselah et al.	T. Asselah, H. Reesink, J. Gerstoft, V. de Ledinghen, P. J. Pockros, M. Robertson, P. Hwang, E. Asante-Appiah, J. Wahl, B. Y. Nguyen, E. Barr, R. Talwani and L. Serfaty	2018	Liver Int.	38	9	1583-1591		https://doi.org/10.1111/liv.1372729454794	HCV Genotype 6a Escape From and Resistance to Velpatasvir, Pibrentasvir, and Sofosbuvir in Robust Infectious Cell Culture Models.	Pham et al.	L. V. Pham, S. Ramirez, J. M. Gottwein, U. Fahnøe, Y. P. Li, J. Pedersen and J. Bukh	2018	Gastroenterology	154	8	2194-2208.e12		https://doi.org/10.1053/j.gastro.2018.02.01729453451	Prevalence and impact of baseline resistance-associated substitutions on the efficacy of ledipasvir/sofosbuvir or simeprevir/sofosbuvir against GT1 HCV infection.	Wang et al.	G. P. Wang, N. Terrault, J. D. Reeves, L. Liu, E. Li, L. Zhao, J. K. Lim, G. Morelli, A. Kuo, J. Levitsky, K. E. Sherman, L. M. Frazier, A. Ramani, J. Peter, L. Akuskevich, M. W. Fried and D. R. Nelson	2018	Sci Rep	8	1	3199		https://doi.org/10.1038/s41598-018-21303-229425404	Nonstructural protein 5A/P32 deletion after failure of ledipasvir/sofosbuvir in hepatitis C virus genotype 1b infection.	Doi et al.	A. Doi, H. Hikita, R. Sakamori, Y. Tahata, Y. Kai, R. Yamada, T. Yakushijin, E. Mita, K. Ohkawa, Y. Imai, K. Furuta, T. Kodama, T. Tatsumi and T. Takehara	2018	Hepatology	68	1	380-383		https://doi.org/10.1002/hep.2983629425396	Resistance analysis of genotype 3 hepatitis C virus indicates subtypes inherently resistant to nonstructural protein 5A inhibitors.	Smith et al.	D. Smith, A. Magri, D. Bonsall, C. L. C. Ip, A. Trebes, A. Brown, P. Piazza, R. Bowden, D. Nguyen, M. A. Ansari, P. Simmonds, E. Barnes and STOP-HCV Consortium	2018	Hepatology					https://doi.org/10.1002/hep.2983729404477	The emergence of NS5B resistance associated substitution S282T after sofosbuvir-based treatment.	Gane et al.	E. J. Gane, S. Metivier, R. Nahass, M. Ryan, C. A. Stedman, E. S. Svarovskaia, H. Mo, B. Doehle, H. Dvory-Sobol, C. Hedskog, M. Lin, D. M. Brainard, J. C. Yang, J. G. McHutchison, M. Sulkowski, Z. Younes and E. Lawitz	2017	Hepatol Commun	1	6	538-549		https://doi.org/10.1002/hep4.106029274866	Efficacy of NS5A Inhibitors Against Hepatitis C Virus Genotypes 1-7 and Escape Variants.	Gottwein et al.	J. M. Gottwein, L. V. Pham, L. S. Mikkelsen, L. Ghanem, S. Ramirez, T. K. H. Scheel, T. H. R. Carlsen and J. Bukh	2018	Gastroenterology	154	5	1435-1448		https://doi.org/10.1053/j.gastro.2017.12.01529274188	The presence of multiple NS5A RASs is associated with the outcome of sofosbuvir and ledipasvir therapy in NS5A inhibitor-naïve patients with chronic HCV genotype 1b infection in a real-world cohort.	Kozuka et al.	R. Kozuka, H. Hai, H. Motoyama, A. Hagihara, H. Fujii, S. Uchida-Kobayashi, H. Morikawa, M. Enomoto, Y. Murakami, N. Kawada and A. Tamori	2018	J. Viral Hepat.	25	5	535-542		https://doi.org/10.1111/jvh.1285029271114	Viral kinetics analysis and virological characterization of treatment failures in patients with chronic hepatitis C treated with sofosbuvir and an NS5A inhibitor.	Fourati et al.	S. Fourati, J. Guedj, S. Chevaliez, T. H. T. Nguyen, F. Roudot-Thoraval, I. Ruiz, A. Soulier, G. Scoazec, A. Varaut, L. Poiteau, M. Francois, A. Mallat, C. Hézode and J. M. Pawlotsky	2018	Aliment. Pharmacol. Ther.	47	5	665-673		https://doi.org/10.1111/apt.1447829221887	Resistance analysis in patients with genotype 1-6 HCV infection treated with sofosbuvir/velpatasvir in the phase III studies.	Hezode et al.	C. Hezode, N. Reau, E. S. Svarovskaia, B. P. Doehle, R. Shanmugam, H. Dvory-Sobol, C. Hedskog, J. McNally, A. Osinusi, D. M. Brainard, M. D. Miller, H. Mo, S. K. Roberts, J. G. O'Leary, S. D. Shafran and S. Zeuzem	2018	J. Hepatol.	68	5	895-903		https://doi.org/10.1016/j.jhep.2017.11.03229152781	Glecaprevir/Pibrentasvir in patients with hepatitis C virus genotype 1 or 4 and past direct-acting antiviral treatment failure.	Poordad et al.	F. Poordad, S. Pol, A. Asatryan, M. Buti, D. Shaw, C. Hézode, F. Felizarta, R. W. Reindollar, S. C. Gordon, S. Pianko, M. W. Fried, D. E. Bernstein, J. Gallant, C. W. Lin, Y. Lei, T. I. Ng, P. Krishnan, S. Kopecky-Bromberg, J. Kort and F. J. Mensa	2018	Hepatology	67	4	1253-1260		https://doi.org/10.1002/hep.2967129146520	Patterns of Resistance-Associated Substitutions in Patients With Chronic HCV Infection Following Treatment With Direct-Acting Antivirals.	Dietz et al.	J. Dietz, S. Susser, J. Vermehren, K. H. Peiffer, G. Grammatikos, A. Berger, P. Ferenci, M. Buti, B. Müllhaupt, B. Hunyady, H. Hinrichsen, S. Mauss, J. Petersen, P. Buggisch, G. Felten, D. Hüppe, G. Knecht, T. Lutz, E. Schott, C. Berg, U. Spengler, T. von Hahn, T. Berg, S. Zeuzem, C. Sarrazin and European HCV Resistance Study Group	2018	Gastroenterology	154	4	976-988.e4		https://doi.org/10.1053/j.gastro.2017.11.00729091342	Ledipasvir/sofosbuvir for treatment of hepatitis C virus in sofosbuvir-experienced, NS5A treatment-naïve patients: Findings from two randomized trials.	Tam et al.	E. Tam, A. F. Luetkemeyer, P. S. Mantry, S. K. Satapathy, P. Ghali, M. Kang, R. Haubrich, X. Shen, L. Ni, G. Camus, A. Copans, L. Rossaro, B. Guyer, R. S. Brown and RESCUE and ACTG A5348 study investigators	2018	Liver Int.	38	6	1010-1021		https://doi.org/10.1111/liv.1361629084747	Antiviral Activity and Resistance Profile of the Next-Generation Hepatitis C Virus NS3/4A Protease Inhibitor Glecaprevir.	Ng et al.	T. I. Ng, R. Tripathi, T. Reisch, L. Lu, T. Middleton, T. A. Hopkins, R. Pithawalla, M. Irvin, T. Dekhtyar, P. Krishnan, G. Schnell, J. Beyer, K. F. McDaniel, J. Ma, G. Wang, L. J. Jiang, Y. S. Or, D. Kempf, T. Pilot-Matias and C. Collins	2018	Antimicrob. Agents Chemother.	62	1			https://doi.org/10.1128/AAC.01620-1728984067	Resistance characterization of ledipasvir and velpatasvir in hepatitis C virus genotype 4.	Camus et al.	G. Camus, B. Han, T. Asselah, D. Hsieh, H. Dvory-Sobol, J. Lu, E. Svarovskaia, R. Martin, B. Parhy, M. D. Miller, D. M. Brainard, K. Kersey, A. Abergel and H. Mo	2018	J. Viral Hepat.	25	2	134-143		https://doi.org/10.1111/jvh.1279528941023	Long-term follow-up of clinical trial patients treated for chronic HCV infection with daclatasvir-based regimens.	Reddy et al.	K. R. Reddy, S. Pol, P. J. Thuluvath, H. Kumada, J. Toyota, K. Chayama, J. Levin, E. J. Lawitz, A. Gadano, W. Ghesquiere, G. Gerken, M. R. Brunetto, C. Y. Peng, M. Silva, S. I. Strasser, J. Heo, F. McPhee, Z. Liu, R. Yang, M. Linaberry and S. Noviello	2018	Liver Int.	38	5	821-833		https://doi.org/10.1111/liv.1359628789880	Response to DAA therapy in the NHS England Early Access Programme for rare HCV subtypes from low and middle income countries.	da Silva Filipe et al.	A. da Silva Filipe, V. Sreenu, J. Hughes, E. Aranday-Cortes, W. L. Irving, G. R. Foster, K. Agarwal, W. Rosenberg, D. Macdonald, P. Richardson, M. A. Aldersley, M. Wiselka, A. Ustianowski, J. McLauchlan and E. C. Thomson	2017	J. Hepatol.	67	6	1348-1350		https://doi.org/10.1016/j.jhep.2017.06.03528783119	Characterization of Naturally Occurring NS5A and NS5B Polymorphisms in Patients Infected with HCV Genotype 3a Treated with Direct-Acting Antiviral Agents.	Bartolini et al.	B. Bartolini, E. Giombini, C. Taibi, R. Lionetti, M. Montalbano, U. Visco-Comandini, G. D'Offizi, M. R. Capobianchi, F. McPhee and A. R. Garbuglia	2017	Viruses	9	8			https://doi.org/10.3390/v908021228595606	Detection of a genetic footprint of the sofosbuvir resistance-associated substitution S282T after HCV treatment failure.	Walker et al.	A. Walker, S. Filke, N. Lübke, M. Obermeier, R. Kaiser, D. Häussinger, J. Timm and H. H. Bock	2017	Virol. J.	14	1	106		https://doi.org/10.1186/s12985-017-0779-428576451	Elbasvir plus grazoprevir in patients with hepatitis C virus infection and stage 4-5 chronic kidney disease: clinical, virological, and health-related quality-of-life outcomes from a phase 3, multicentre, randomised, double-blind, placebo-controlled trial.	Bruchfeld et al.	A. Bruchfeld, D. Roth, P. Martin, D. R. Nelson, S. Pol, M. C. Londoño, H. Monsour, M. Silva, P. Hwang, J. M. Arduino, M. Robertson, B. Y. Nguyen, J. Wahl, E. Barr and W. Greaves	2017	Lancet Gastroenterol Hepatol	2	8	585-594		https://doi.org/10.1016/S2468-1253(17)30116-428564569	Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection.	Bourlière et al.	M. Bourlière, S. C. Gordon, S. L. Flamm, C. L. Cooper, A. Ramji, M. Tong, N. Ravendhran, J. M. Vierling, T. T. Tran, S. Pianko, M. B. Bansal, V. de Lédinghen, R. H. Hyland, L. M. Stamm, H. Dvory-Sobol, E. Svarovskaia, J. Zhang, K. C. Huang, G. M. Subramanian, D. M. Brainard, J. G. McHutchison, E. C. Verna, P. Buggisch, C. S. Landis, Z. H. Younes, M. P. Curry, S. I. Strasser, E. R. Schiff, K. R. Reddy, M. P. Manns, K. V. Kowdley, S. Zeuzem and POLARIS-1 and POLARIS-4 Investigators	2017	N. Engl. J. Med.	376	22	2134-2146		https://doi.org/10.1056/NEJMoa161351228498551	Sofosbuvir-velpatasvir with ribavirin for 24 weeks in hepatitis C virus patients previously treated with a direct-acting antiviral regimen.	Gane et al.	E. J. Gane, M. L. Shiffman, K. Etzkorn, G. Morelli, C. A. M. Stedman, M. N. Davis, F. Hinestrosa, H. Dvory-Sobol, K. C. Huang, A. Osinusi, J. McNally, D. M. Brainard, J. G. McHutchison, A. J. Thompson, M. S. Sulkowski and GS-US-342-1553 Investigators	2017	Hepatology	66	4	1083-1089		https://doi.org/10.1002/hep.2925628470815	Efficacy of 12 or 18 weeks of elbasvir plus grazoprevir with ribavirin in treatment-naïve, noncirrhotic HCV genotype 3-infected patients.	Gane et al.	E. Gane, R. Nahass, V. Luketic, E. Asante-Appiah, P. Hwang, M. Robertson, J. Wahl, E. Barr and B. Haber	2017	J. Viral Hepat.	24	10	895-899		https://doi.org/10.1111/jvh.1271928416549	Antiviral Activity and Resistance Analysis of NS3/4A Protease Inhibitor Grazoprevir and NS5A Inhibitor Elbasvir in Hepatitis C Virus GT4 Replicons.	Asante-Appiah et al.	E. Asante-Appiah, S. Curry, P. McMonagle, P. Ingravallo, R. Chase, D. Nickle, P. Qiu, A. Howe and F. C. Lahser	2017	Antimicrob. Agents Chemother.	61	7			https://doi.org/10.1128/AAC.00363-1728412293	Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis.	Kwo et al.	P. Y. Kwo, F. Poordad, A. Asatryan, S. Wang, D. L. Wyles, T. Hassanein, F. Felizarta, M. S. Sulkowski, E. Gane, B. Maliakkal, J. S. Overcash, S. C. Gordon, A. J. Muir, H. Aguilar, K. Agarwal, G. J. Dore, C. W. Lin, R. Liu, S. S. Lovell, T. I. Ng, J. Kort and F. J. Mensa	2017	J. Hepatol.	67	2	263-271		https://doi.org/10.1016/j.jhep.2017.03.03928369411	Sofosbuvir-Daclatasvir-Simeprevir Plus Ribavirin in Direct-Acting Antiviral-Experienced Patients With Hepatitis C.	Hézode et al.	C. Hézode, S. Fourati, S. Chevaliez, G. Scoazec, A. Soulier, A. Varaut, M. François, I. Ruiz, F. Roudot-Thoraval, A. Mallat and J. M. Pawlotsky	2017	Clin. Infect. Dis.	64	11	1615-1618		https://doi.org/10.1093/cid/cix21428332272	Clinical evaluation of sofosbuvir/ledipasvir in patients with chronic hepatitis C genotype 1 with and without prior daclatasvir/asunaprevir therapy.	Iio et al.	E. Iio, N. Shimada, K. Takaguchi, T. Senoh, Y. Eguchi, M. Atsukawa, A. Tsubota, H. Abe, K. Kato, A. Kusakabe, T. Miyaki, K. Matsuura, K. Matsunami, N. Shinkai, K. Fujiwara, S. Nojiri and Y. Tanaka	2017	Hepatol. Res.	47	12	1308-1316		https://doi.org/10.1111/hepr.1289828193664	Antiviral Activity and Resistance Profile of the Next-Generation Hepatitis C Virus NS5A Inhibitor Pibrentasvir.	Ng et al.	T. I. Ng, P. Krishnan, T. Pilot-Matias, W. Kati, G. Schnell, J. Beyer, T. Reisch, L. Lu, T. Dekhtyar, M. Irvin, R. Tripathi, C. Maring, J. T. Randolph, R. Wagner and C. Collins	2017	Antimicrob. Agents Chemother.	61	5			https://doi.org/10.1128/AAC.02558-1628193518	Safety and Efficacy of Elbasvir/Grazoprevir in Patients With Hepatitis C Virus Infection and Compensated Cirrhosis: An Integrated Analysis.	Jacobson et al.	I. M. Jacobson, E. Lawitz, P. Y. Kwo, C. Hézode, C. Y. Peng, A. Y. M. Howe, P. Hwang, J. Wahl, M. Robertson, E. Barr and B. A. Haber	2017	Gastroenterology	152	6	1372-1382.e2		https://doi.org/10.1053/j.gastro.2017.01.05028128852	Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct-acting antiviral treatment.	Poordad et al.	F. Poordad, F. Felizarta, A. Asatryan, M. S. Sulkowski, R. W. Reindollar, C. S. Landis, S. C. Gordon, S. L. Flamm, M. W. Fried, D. E. Bernstein, C. W. Lin, R. Liu, S. S. Lovell, T. I. Ng, J. Kort and F. J. Mensa	2017	Hepatology	66	2	389-397		https://doi.org/10.1002/hep.2908128105744	Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies.	Di Maio et al.	V. C. Di Maio, V. Cento, I. Lenci, M. Aragri, P. Rossi, S. Barbaliscia, M. Melis, G. Verucchi, C. F. Magni, E. Teti, A. Bertoli, F. Antonucci, M. C. Bellocchi, V. Micheli, C. Masetti, S. Landonio, S. Francioso, F. Santopaolo, A. M. Pellicelli, V. Calvaruso, L. Gianserra, M. Siciliano, D. Romagnoli, R. Cozzolongo, A. Grieco, J. Vecchiet, F. Morisco, M. Merli, G. Brancaccio, A. Di Biagio, E. Loggi, C. M. Mastroianni, V. Pace Palitti, P. Tarquini, M. Puoti, G. Taliani, L. Sarmati, A. Picciotto, V. Vullo, N. Caporaso, M. Paoloni, C. Pasquazzi, G. Rizzardini, G. Parruti, A. Craxì, S. Babudieri, M. Andreoni, M. Angelico, C. F. Perno, F. Ceccherini-Silberstein and HCV Italian Resistance Network Study Group	2017	Liver Int.	37	4	514-528		https://doi.org/10.1111/liv.1332728078469	New resistance-associated substitutions and failure of dual oral therapy with daclatasvir and asunaprevir.	Mawatari et al.	S. Mawatari, K. Oda, K. Tabu, S. Ijuin, K. Kumagai, Y. Inada, H. Uto, Y. Hiramine, T. Kure, K. Fujisaki, M. Hashiguchi, T. Hori, A. Oshige, D. Imanaka, A. Saishoji, O. Taniyama, H. Sakae, T. Tamai, A. Moriuchi and A. Ido	2017	J. Gastroenterol.	52	7	855-867		https://doi.org/10.1007/s00535-016-1303-027923693	Post-treatment resistance analysis of hepatitis C virus from phase II and III clinical trials of ledipasvir/sofosbuvir.	Wyles et al.	D. Wyles, H. Dvory-Sobol, E. S. Svarovskaia, B. P. Doehle, R. Martin, N. H. Afdhal, K. V. Kowdley, E. Lawitz, D. M. Brainard, M. D. Miller, H. Mo and E. J. Gane	2017	J. Hepatol.	66	4	703-710		https://doi.org/10.1016/j.jhep.2016.11.02227873094	The combination of elbasvir and grazoprevir for the treatment of chronic HCV infection in Japanese patients: a randomized phase II/III study.	Kumada et al.	H. Kumada, Y. Suzuki, Y. Karino, K. Chayama, N. Kawada, T. Okanoue, Y. Itoh, S. Mochida, H. Toyoda, H. Yoshiji, S. Takaki, N. Yatsuzuka, E. Yodoya, T. Iwasa, G. Fujimoto, M. N. Robertson, S. Black, L. Caro and J. Wahl	2017	J. Gastroenterol.	52	4	520-533		https://doi.org/10.1007/s00535-016-1285-y27537841	Elbasvir-Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy: A Randomized Trial.	Dore et al.	G. J. Dore, F. Altice, A. H. Litwin, O. Dalgard, E. J. Gane, O. Shibolet, A. Luetkemeyer, R. Nahass, C. Y. Peng, B. Conway, J. Grebely, A. Y. Howe, I. N. Gendrano, E. Chen, H. C. Huang, F. J. Dutko, D. C. Nickle, B. Y. Nguyen, J. Wahl, E. Barr, M. N. Robertson, H. L. Platt and C-EDGE CO-STAR Study Group	2016	Ann. Intern. Med.	165	9	625-634		https://doi.org/10.7326/M16-081627773808	Regulatory Analysis of Effects of Hepatitis C Virus NS5A Polymorphisms on Efficacy of Elbasvir and Grazoprevir.	Komatsu et al.	T. E. Komatsu, S. Boyd, A. Sherwat, L. Tracy, L. K. Naeger, J. J. O'Rear and P. R. Harrington	2017	Gastroenterology	152	3	586-597		https://doi.org/10.1053/j.gastro.2016.10.01727720838	Effectiveness of Elbasvir and Grazoprevir Combination, With or Without Ribavirin, for Treatment-Experienced Patients With Chronic Hepatitis C Infection.	Kwo et al.	P. Kwo, E. J. Gane, C. Y. Peng, B. Pearlman, J. M. Vierling, L. Serfaty, M. Buti, S. Shafran, P. Stryszak, L. Lin, J. Gress, S. Black, F. J. Dutko, M. Robertson, J. Wahl, L. Lupinacci, E. Barr and B. Haber	2017	Gastroenterology	152	1	164-175.e4		https://doi.org/10.1053/j.gastro.2016.09.04527605597	Characterization of NS5A polymorphisms and their impact on response rates in patients with HCV genotype 2 treated with daclatasvir-based regimens.	Zhou et al.	N. Zhou, Z. Han, S. Hartman-Neumann, B. DeGray, J. Ueland, V. Vellucci, D. Hernandez and F. McPhee	2016	J. Antimicrob. Chemother.	71	12	3495-3505		https://doi.org/10.1093/jac/dkw33627597318	Effectiveness and safety of daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: Systematic review and meta-analysis.	Wang et al.	H. L. Wang, X. Lu, X. Yang and N. Xu	2017	J. Gastroenterol. Hepatol.	32	1	45-52		https://doi.org/10.1111/jgh.1358727453546	Robust HCV Genotype 3a Infectious Cell Culture System Permits Identification of Escape Variants With Resistance to Sofosbuvir.	Ramirez et al.	S. Ramirez, L. S. Mikkelsen, J. M. Gottwein and J. Bukh	2016	Gastroenterology	151	5	973-985.e2		https://doi.org/10.1053/j.gastro.2016.07.01327353271	Clinical Resistance to Velpatasvir (GS-5816), a Novel Pan-Genotypic Inhibitor of the Hepatitis C Virus NS5A Protein.	Lawitz et al.	E. J. Lawitz, H. Dvory-Sobol, B. P. Doehle, A. S. Worth, J. McNally, D. M. Brainard, J. O. Link, M. D. Miller and H. Mo	2016	Antimicrob. Agents Chemother.	60	9	5368-78		https://doi.org/10.1128/AAC.00763-1627351341	Ledipasvir plus sofosbuvir for 12 weeks in patients with hepatitis C genotype 4 infection.	Abergel et al.	A. Abergel, S. Metivier, D. Samuel, D. Jiang, K. Kersey, P. S. Pang, E. Svarovskaia, S. J. Knox, V. Loustaud-Ratti and T. Asselah	2016	Hepatology	64	4	1049-56		https://doi.org/10.1002/hep.2870627236547	Efficacy of daclatasvir/asunaprevir according to resistance-associated variants in chronic hepatitis C with genotype 1.	Iio et al.	E. Iio, N. Shimada, H. Abe, M. Atsukawa, K. Yoshizawa, K. Takaguchi, Y. Eguchi, H. Nomura, T. Kuramitsu, J. H. Kang, T. Matsui, N. Hirashima, A. Tsubota, A. Kusakabe, I. Hasegawa, T. Miyaki, N. Shinkai, K. Fujiwara, S. Nojiri and Y. Tanaka	2017	J. Gastroenterol.	52	1	94-103		https://doi.org/10.1007/s00535-016-1225-x27025835	12 Weeks of Daclatasvir in Combination With Sofosbuvir for HIV-HCV Coinfection (ALLY-2 Study): Efficacy and Safety by HIV Combination Antiretroviral Regimens.	Luetkemeyer et al.	A. F. Luetkemeyer, C. McDonald, M. Ramgopal, S. Noviello, R. Bhore and P. Ackerman	2016	Clin. Infect. Dis.	62	12	1489-96		https://doi.org/10.1093/cid/ciw16327009831	All-oral daclatasvir plus asunaprevir for chronic hepatitis C virus (HCV) genotype 1b infection: a sub-analysis in Asian patients from the HALLMARK DUAL study.	Kao et al.	J. H. Kao, Y. J. Lee, J. Heo, S. H. Ahn, Y. S. Lim, C. Y. Peng, T. T. Chang, A. Torbeyns, E. Hughes, R. Bhore and S. Noviello	2016	Liver Int.	36	10	1433-41		https://doi.org/10.1111/liv.1312827003037	A phase 3, open-label study of daclatasvir plus asunaprevir in Asian patients with chronic hepatitis C virus genotype 1b infection who are ineligible for or intolerant to interferon alfa therapies with or without ribavirin.	Wei et al.	L. Wei, M. Zhang, M. Xu, W. L. Chuang, W. Lu, W. Xie, Z. Jia, G. Gong, Y. Li, S. H. Bae, Y. F. Yang, Q. Xie, S. Lin, X. Chen, J. Niu, J. Jia, T. Garimella, A. Torbeyns, F. McPhee, M. Treitel, P. D. Yin and L. Mo	2016	J. Gastroenterol. Hepatol.	31	11	1860-1867		https://doi.org/10.1111/jgh.1337926926625	The Combination of Grazoprevir, a Hepatitis C Virus (HCV) NS3/4A Protease Inhibitor, and Elbasvir, an HCV NS5A Inhibitor, Demonstrates a High Genetic Barrier to Resistance in HCV Genotype 1a Replicons.	Lahser et al.	F. C. Lahser, K. Bystol, S. Curry, P. McMonagle, E. Xia, P. Ingravallo, R. Chase, R. Liu, T. Black, D. Hazuda, A. Y. Howe and E. Asante-Appiah	2016	Antimicrob. Agents Chemother.	60	5	2954-64		https://doi.org/10.1128/AAC.00051-1626878268	Development of rare resistance-associated variants that are extremely tolerant against NS5A inhibitors during daclatasvir/asunaprevir therapy by a two-hit mechanism.	Uchida et al.	Y. Uchida, J. I. Kouyama, K. Naiki, K. Sugawara, M. Inao, Y. Imai, N. Nakayama and S. Mochida	2016	Hepatol. Res.	46	12	1234-1246		https://doi.org/10.1111/hepr.1267326822022	Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: A randomized phase III study (ALLY-3+).	Leroy et al.	V. Leroy, P. Angus, J. P. Bronowicki, G. J. Dore, C. Hezode, S. Pianko, S. Pol, K. Stuart, E. Tse, F. McPhee, R. Bhore, M. J. Jimenez-Exposito and A. J. Thompson	2016	Hepatology	63	5	1430-41		https://doi.org/10.1002/hep.2847326778412	High antiviral activity of NS5A inhibitor ABT-530 with paritaprevir/ritonavir and ribavirin against hepatitis C virus genotype 3 infection.	Poordad et al.	F. Poordad, C. S. Landis, A. Asatryan, D. F. Jackson, T. I. Ng, B. Fu, C. W. Lin, B. Yao and J. Kort	2016	Liver Int.	36	8	1125-32		https://doi.org/10.1111/liv.1306726603202	L159F and V321A Sofosbuvir-Associated Hepatitis C Virus NS5B Substitutions.	Svarovskaia et al.	E. S. Svarovskaia, E. Gane, H. Dvory-Sobol, R. Martin, B. Doehle, C. Hedskog, I. M. Jacobson, D. R. Nelson, E. Lawitz, D. M. Brainard, J. G. McHutchison, M. D. Miller and H. Mo	2016	J. Infect. Dis.	213	8	1240-7		https://doi.org/10.1093/infdis/jiv56426575258	Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection.	Foster et al.	G. R. Foster, N. Afdhal, S. K. Roberts, N. Bräu, E. J. Gane, S. Pianko, E. Lawitz, A. Thompson, M. L. Shiffman, C. Cooper, W. J. Towner, B. Conway, P. Ruane, M. Bourlière, T. Asselah, T. Berg, S. Zeuzem, W. Rosenberg, K. Agarwal, C. A. Stedman, H. Mo, H. Dvory-Sobol, L. Han, J. Wang, J. McNally, A. Osinusi, D. M. Brainard, J. G. McHutchison, F. Mazzotta, T. T. Tran, S. C. Gordon, K. Patel, N. Reau, A. Mangia, M. Sulkowski, ASTRAL-2  Investigators and ASTRAL-3 Investigators	2015	N. Engl. J. Med.	373	27	2608-17		https://doi.org/10.1056/NEJMoa151261226569658	Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis.	Curry et al.	M. P. Curry, J. G. O'Leary, N. Bzowej, A. J. Muir, K. M. Korenblat, J. M. Fenkel, K. R. Reddy, E. Lawitz, S. L. Flamm, T. Schiano, L. Teperman, R. Fontana, E. Schiff, M. Fried, B. Doehle, D. An, J. McNally, A. Osinusi, D. M. Brainard, J. G. McHutchison, R. S. Brown, M. Charlton and ASTRAL-4 Investigators	2015	N. Engl. J. Med.	373	27	2618-28		https://doi.org/10.1056/NEJMoa151261426521268	Successful Retreatment of Chronic HCV Genotype-1 Infection With Ledipasvir and Sofosbuvir After Initial Short Course Therapy With Direct-Acting Antiviral Regimens.	Wilson et al.	E. M. Wilson, S. Kattakuzhy, S. Sidharthan, Z. Sims, L. Tang, M. McLaughlin, A. Price, A. Nelson, R. Silk, C. Gross, E. Akoth, H. Mo, G. M. Subramanian, P. S. Pang, J. G. McHutchison, A. Osinusi, H. Masur, A. Kohli and S. Kottilil	2016	Clin. Infect. Dis.	62	3	280-288		https://doi.org/10.1093/cid/civ87426453968	Daclatasvir plus simeprevir with or without ribavirin for the treatment of chronic hepatitis C virus genotype 1 infection.	Zeuzem et al.	S. Zeuzem, C. Hézode, J. P. Bronowicki, V. Loustaud-Ratti, F. Gea, M. Buti, A. Olveira, T. Banyai, M. T. Al-Assi, J. Petersen, D. Thabut, A. Gadano, R. Pruitt, M. Makara, M. Bourlière, S. Pol, M. Beumont-Mauviel, S. Ouwerkerk-Mahadevan, G. Picchio, M. Bifano, F. McPhee, N. Boparai, K. Cheung, E. A. Hughes, S. Noviello and LEAGUE-1 Study Team	2016	J. Hepatol.	64	2	292-300		https://doi.org/10.1016/j.jhep.2015.09.02426423374	Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial.	Rockstroh et al.	J. K. Rockstroh, M. Nelson, C. Katlama, J. Lalezari, J. Mallolas, M. Bloch, G. V. Matthews, M. S. Saag, P. J. Zamor, C. Orkin, J. Gress, S. Klopfer, M. Shaughnessy, J. Wahl, B. Y. Nguyen, E. Barr, H. L. Platt, M. N. Robertson and M. Sulkowski	2015	Lancet HIV	2	8	e319-27		https://doi.org/10.1016/S2352-3018(15)00114-926371152	Grazoprevir, Elbasvir, and Ribavirin for Chronic Hepatitis C Virus Genotype 1 Infection After Failure of Pegylated Interferon and Ribavirin With an Earlier-Generation Protease Inhibitor: Final 24-Week Results From C-SALVAGE.	Buti et al.	M. Buti, S. C. Gordon, E. Zuckerman, E. Lawitz, J. L. Calleja, H. Hofer, C. Gilbert, J. Palcza, A. Y. Howe, M. J. DiNubile, M. N. Robertson, J. Wahl, E. Barr and X. Forns	2016	Clin. Infect. Dis.	62	1	32-6		https://doi.org/10.1093/cid/civ72226303801	Susceptibilities of genotype 1a, 1b, and 3 hepatitis C virus variants to the NS5A inhibitor elbasvir.	Liu et al.	R. Liu, S. Curry, P. McMonagle, W. W. Yeh, S. W. Ludmerer, P. A. Jumes, W. L. Marshall, S. Kong, P. Ingravallo, S. Black, I. Pak, M. J. DiNubile and A. Y. Howe	2015	Antimicrob. Agents Chemother.	59	11	6922-9		https://doi.org/10.1128/AAC.01390-1526196665	Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1.	Naggie et al.	S. Naggie, C. Cooper, M. Saag, K. Workowski, P. Ruane, W. J. Towner, K. Marks, A. Luetkemeyer, R. P. Baden, P. E. Sax, E. Gane, J. Santana-Bagur, L. M. Stamm, J. C. Yang, P. German, H. Dvory-Sobol, L. Ni, P. S. Pang, J. G. McHutchison, C. A. Stedman, J. O. Morales-Ramirez, N. Bräu, D. Jayaweera, A. E. Colson, P. Tebas, D. K. Wong, D. Dieterich, M. Sulkowski and ION-4 Investigators	2015	N. Engl. J. Med.	373	8	705-13		https://doi.org/10.1056/NEJMoa150131526196502	Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1.	Wyles et al.	D. L. Wyles, P. J. Ruane, M. S. Sulkowski, D. Dieterich, A. Luetkemeyer, T. R. Morgan, K. E. Sherman, R. Dretler, D. Fishbein, J. C. Gathe, S. Henn, F. Hinestrosa, C. Huynh, C. McDonald, A. Mills, E. T. Overton, M. Ramgopal, B. Rashbaum, G. Ray, A. Scarsella, J. Yozviak, F. McPhee, Z. Liu, E. Hughes, P. D. Yin, S. Noviello, P. Ackerman and ALLY-2 Investigators	2015	N. Engl. J. Med.	373	8	714-25		https://doi.org/10.1056/NEJMoa150315326170396	NS5A Sequence Heterogeneity and Mechanisms of Daclatasvir Resistance in Hepatitis C Virus Genotype 4 Infection.	Zhou et al.	N. Zhou, D. Hernandez, J. Ueland, X. Yang, F. Yu, K. Sims, P. D. Yin and F. McPhee	2016	J. Infect. Dis.	213	2	206-15		https://doi.org/10.1093/infdis/jiv37925847509	Sofosbuvir plus pegylated interferon and ribavirin in patients with genotype 1 hepatitis C virus in whom previous therapy with direct-acting antivirals has failed.	Pol et al.	S. Pol, M. S. Sulkowski, T. Hassanein, E. J. Gane, L. Liu, H. Mo, B. Doehle, B. Kanwar, D. Brainard, G. M. Subramanian, W. T. Symonds, J. G. McHutchison, R. G. Nahass, M. Bennett and I. M. Jacobson	2015	Hepatology	62	1	129-34		https://doi.org/10.1002/hep.2783625659285	Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study.	Molina et al.	J. M. Molina, C. Orkin, D. M. Iser, F. X. Zamora, M. Nelson, C. Stephan, B. Massetto, A. Gaggar, L. Ni, E. Svarovskaia, D. Brainard, G. M. Subramanian, J. G. McHutchison, M. Puoti, J. K. Rockstroh and PHOTON-2 study team	2015	Lancet	385	9973	1098-106		https://doi.org/10.1016/S0140-6736(14)62483-125614962	All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study.	Nelson et al.	D. R. Nelson, J. N. Cooper, J. P. Lalezari, E. Lawitz, P. J. Pockros, N. Gitlin, B. F. Freilich, Z. H. Younes, W. Harlan, R. Ghalib, G. Oguchi, P. J. Thuluvath, G. Ortiz-Lasanta, M. Rabinovitz, D. Bernstein, M. Bennett, T. Hawkins, N. Ravendhran, A. M. Sheikh, P. Varunok, K. V. Kowdley, D. Hennicken, F. McPhee, K. Rana, E. A. Hughes and ALLY-3 Study Team	2015	Hepatology	61	4	1127-35		https://doi.org/10.1002/hep.2772625467591	Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial.	Lawitz et al.	E. Lawitz, E. Gane, B. Pearlman, E. Tam, W. Ghesquiere, D. Guyader, L. Alric, J. P. Bronowicki, L. Lester, W. Sievert, R. Ghalib, L. Balart, F. Sund, M. Lagging, F. Dutko, M. Shaughnessy, P. Hwang, A. Y. Howe, J. Wahl, M. Robertson, E. Barr and B. Haber	2015	Lancet	385	9973	1075-86		https://doi.org/10.1016/S0140-6736(14)61795-525467560	Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial.	Sulkowski et al.	M. Sulkowski, C. Hezode, J. Gerstoft, J. M. Vierling, J. Mallolas, S. Pol, M. Kugelmas, A. Murillo, N. Weis, R. Nahass, O. Shibolet, L. Serfaty, M. Bourliere, E. DeJesus, E. Zuckerman, F. Dutko, M. Shaughnessy, P. Hwang, A. Y. Howe, J. Wahl, M. Robertson, E. Barr and B. Haber	2015	Lancet	385	9973	1087-97		https://doi.org/10.1016/S0140-6736(14)61793-125322962	Sofosbuvir with peginterferon-ribavirin for 12 weeks in previously treated patients with hepatitis C genotype 2 or 3 and cirrhosis.	Lawitz et al.	E. Lawitz, F. Poordad, D. M. Brainard, R. H. Hyland, D. An, H. Dvory-Sobol, W. T. Symonds, J. G. McHutchison and F. E. Membreno	2015	Hepatology	61	3	769-75		https://doi.org/10.1002/hep.2756725266287	Infrequent development of resistance in genotype 1-6 hepatitis C virus-infected subjects treated with sofosbuvir in phase 2 and 3 clinical trials.	Svarovskaia et al.	E. S. Svarovskaia, H. Dvory-Sobol, N. Parkin, C. Hebner, V. Gontcharova, R. Martin, W. Ouyang, B. Han, S. Xu, K. Ku, S. Chiu, E. Gane, I. M. Jacobson, D. R. Nelson, E. Lawitz, D. L. Wyles, N. Bekele, D. Brainard, W. T. Symonds, J. G. McHutchison, M. D. Miller and H. Mo	2014	Clin. Infect. Dis.	59	12	1666-74		https://doi.org/10.1093/cid/ciu69724936600	Comparison of daclatasvir resistance barriers on NS5A from hepatitis C virus genotypes 1 to 6: implications for cross-genotype activity.	Wang et al.	C. Wang, L. Jia, D. R. O'Boyle, J. H. Sun, K. Rigat, L. Valera, P. Nower, X. Huang, B. Kienzle, S. Roberts, M. Gao and R. A. Fridell	2014	Antimicrob. Agents Chemother.	58	9	5155-63		https://doi.org/10.1128/AAC.02788-1424795201	Sofosbuvir and ribavirin in HCV genotypes 2 and 3.	Zeuzem et al.	S. Zeuzem, G. M. Dusheiko, R. Salupere, A. Mangia, R. Flisiak, R. H. Hyland, A. Illeperuma, E. Svarovskaia, D. M. Brainard, W. T. Symonds, G. M. Subramanian, J. G. McHutchison, O. Weiland, H. W. Reesink, P. Ferenci, C. Hézode, R. Esteban and VALENCE Investigators	2014	N. Engl. J. Med.	370	21	1993-2001		https://doi.org/10.1056/NEJMoa131614524448487	Virological escape in HCV genotype-1-infected patients receiving daclatasvir plus ribavirin and peginterferon alfa-2a or alfa-2b.	McPhee et al.	F. McPhee, D. Hernandez, N. Zhou, F. Yu, J. Ueland, A. Monikowski, K. Chayama, J. Toyota, N. Izumi, O. Yokosuka, N. Kawada, Y. Osaki, E. A. Hughes, H. Watanabe, H. Ishikawa and H. Kumada	2014	Antivir. Ther. (Lond.)	19	5	479-90		https://doi.org/10.3851/IMP272924444658	Randomized trial of daclatasvir and asunaprevir with or without PegIFN/RBV for hepatitis C virus genotype 1 null responders.	Lok et al.	A. S. Lok, D. F. Gardiner, C. Hézode, E. J. Lawitz, M. Bourlière, G. T. Everson, P. Marcellin, M. Rodriguez-Torres, S. Pol, L. Serfaty, T. Eley, S. P. Huang, J. Li, M. Wind-Rotolo, F. Yu, F. McPhee, D. M. Grasela and C. Pasquinelli	2014	J. Hepatol.	60	3	490-9		https://doi.org/10.1016/j.jhep.2013.10.01924154738	In vivo emergence of a novel mutant L159F/L320F in the NS5B polymerase confers low-level resistance to the HCV polymerase inhibitors mericitabine and sofosbuvir.	Tong et al.	X. Tong, S. Le Pogam, L. Li, K. Haines, K. Piso, V. Baronas, J. M. Yan, S. S. So, K. Klumpp and I. Nájera	2014	J. Infect. Dis.	209	5	668-75		https://doi.org/10.1093/infdis/jit56224127258	Discovery of MK-8742: an HCV NS5A inhibitor with broad genotype activity.	Coburn et al.	C. A. Coburn, P. T. Meinke, W. Chang, C. M. Fandozzi, D. J. Graham, B. Hu, Q. Huang, S. Kargman, J. Kozlowski, R. Liu, J. A. McCauley, A. A. Nomeir, R. M. Soll, J. P. Vacca, D. Wang, H. Wu, B. Zhong, D. B. Olsen and S. W. Ludmerer	2013	ChemMedChem	8	12	1930-40		https://doi.org/10.1002/cmdc.20130034323384816	Natural prevalence of NS5A polymorphisms in subjects infected with hepatitis C virus genotype 3 and their effects on the antiviral activity of NS5A inhibitors.	Hernandez et al.	D. Hernandez, N. Zhou, J. Ueland, A. Monikowski and F. McPhee	2013	J. Clin. Virol.	57	1	13-8		https://doi.org/10.1016/j.jcv.2012.12.02023089758	In vitro activity of daclatasvir on hepatitis C virus genotype 3 NS5A.	Wang et al.	C. Wang, L. Valera, L. Jia, M. J. Kirk, M. Gao and R. A. Fridell	2013	Antimicrob. Agents Chemother.	57	1	611-3		https://doi.org/10.1128/AAC.01874-1222850513	Effect on hepatitis C virus replication of combinations of direct-acting antivirals, including NS5A inhibitor daclatasvir.	Pelosi et al.	L. A. Pelosi, S. Voss, M. Liu, M. Gao and J. A. Lemm	2012	Antimicrob. Agents Chemother.	56	10	5230-9		https://doi.org/10.1128/AAC.01209-1222430955	Genotype and subtype profiling of PSI-7977 as a nucleotide inhibitor of hepatitis C virus.	Lam et al.	A. M. Lam, C. Espiritu, S. Bansal, H. M. Micolochick Steuer, C. Niu, V. Zennou, M. Keilman, Y. Zhu, S. Lan, M. J. Otto and P. A. Furman	2012	Antimicrob. Agents Chemother.	56	6	3359-68		https://doi.org/10.1128/AAC.00054-1222256805	Preliminary study of two antiviral agents for hepatitis C genotype 1.	Lok et al.	A. S. Lok, D. F. Gardiner, E. Lawitz, C. Martorell, G. T. Everson, R. Ghalib, R. Reindollar, V. Rustgi, F. McPhee, M. Wind-Rotolo, A. Persson, K. Zhu, D. I. Dimitrova, T. Eley, T. Guo, D. M. Grasela and C. Pasquinelli	2012	N. Engl. J. Med.	366	3	216-24		https://doi.org/10.1056/NEJMoa110443022234905	Impact of a baseline polymorphism on the emergence of resistance to the hepatitis C virus nonstructural protein 5A replication complex inhibitor, BMS-790052.	Sun et al.	J. H. Sun, D. R. O'Boyle Ii, Y. Zhang, C. Wang, P. Nower, L. Valera, S. Roberts, R. E. Nettles, R. A. Fridell and M. Gao	2012	Hepatology	55	6	1692-9		https://doi.org/10.1002/hep.2558122214777	Hepatitis C virus RNA elimination and development of resistance in replicon cells treated with BMS-790052.	Wang et al.	C. Wang, H. Huang, L. Valera, J. H. Sun, D. R. O'Boyle, P. T. Nower, L. Jia, D. Qiu, X. Huang, A. Altaf, M. Gao and R. A. Fridell	2012	Antimicrob. Agents Chemother.	56	3	1350-8		https://doi.org/10.1128/AAC.05977-1122203595	In vitro activity of BMS-790052 on hepatitis C virus genotype 4 NS5A.	Wang et al.	C. Wang, L. Jia, H. Huang, D. Qiu, L. Valera, X. Huang, J. H. Sun, P. T. Nower, D. R. O'Boyle, M. Gao and R. A. Fridell	2012	Antimicrob. Agents Chemother.	56	3	1588-90		https://doi.org/10.1128/AAC.06169-1121809362	Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS-790052 in humans: in vitro and in vivo correlations.	Fridell et al.	R. A. Fridell, C. Wang, J. H. Sun, D. R. O'Boyle, P. Nower, L. Valera, D. Qiu, S. Roberts, X. Huang, B. Kienzle, M. Bifano, R. E. Nettles and M. Gao	2011	Hepatology	54	6	1924-35		https://doi.org/10.1002/hep.2459421593143	Distinct functions of NS5A in hepatitis C virus RNA replication uncovered by studies with the NS5A inhibitor BMS-790052.	Fridell et al.	R. A. Fridell, D. Qiu, L. Valera, C. Wang, R. E. Rose and M. Gao	2011	J. Virol.	85	14	7312-20		https://doi.org/10.1128/JVI.00253-1120585111	Resistance analysis of the hepatitis C virus NS5A inhibitor BMS-790052 in an in vitro replicon system.	Fridell et al.	R. A. Fridell, D. Qiu, C. Wang, L. Valera and M. Gao	2010	Antimicrob. Agents Chemother.	54	9	3641-50		https://doi.org/10.1128/AAC.00556-1020410884	Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect.	Gao et al.	M. Gao, R. E. Nettles, M. Belema, L. B. Snyder, V. N. Nguyen, R. A. Fridell, M. H. Serrano-Wu, D. R. Langley, J. H. Sun, D. R. O'Boyle, J. A. Lemm, C. Wang, J. O. Knipe, C. Chien, R. J. Colonno, D. M. Grasela, N. A. Meanwell and L. G. Hamann	2010	Nature	465	7294	96-100		https://doi.org/10.1038/nature0896030957170	An open-label, randomized, active control trial of 8 versus 12 weeks of elbasvir/grazoprevir for treatment-naïve chronic hepatitis C genotype 1b patients with mild fibrosis (EGALITE): Impact of baseline viral loads and NS5A resistance-associated substitution.	Huang et al.	C. F. Huang, C. H. Hung, P. N. Cheng, M. J. Bair, Y. H. Huang, J. H. Kao, S. J. Hsu, P. L. Lee, J. J. Chen, R. N. Chien, C. Y. Peng, C. Y. Lin, T. Y. Hsieh, C. H. Cheng, C. Y. Dai, J. F. Huang, W. L. Chuang and M. L. Yu	2019	J. Infect. Dis.					https://doi.org/10.1093/infdis/jiz15430127629	Characterization of hepatitis C virus resistance to grazoprevir reveals complex patterns of mutations following on-treatment breakthrough that are not observed at relapse.	Bonsall et al.	D. Bonsall, S. Black, A. Y. Howe, R. Chase, P. Ingravallo, I. Pak, A. Brown, D. A. Smith, R. Bowden and E. Barnes	2018	Infect Drug Resist	11		1119-1135		https://doi.org/10.2147/IDR.S15658128228479	Unraveling the structural basis of grazoprevir potency against clinically relevant substitutions in hepatitis C virus NS3/4A protease from genotype 1a.	Guo et al.	Z. Guo, S. Black, Y. Hu, P. McMonagle, P. Ingravallo, R. Chase, S. Curry and E. Asante-Appiah	2017	J. Biol. Chem.	292	15	6202-6212		https://doi.org/10.1074/jbc.M116.77299627291249	Efficacy and safety of grazoprevir + ribavirin for 12 or 24 weeks in treatment-naïve patients with hepatitis C virus genotype 1 infection.	Gane et al.	E. Gane, Z. Ben Ari, L. Mollison, E. Zuckerman, R. Bruck, Y. Baruch, A. Y. Howe, J. Wahl, S. Bhanja, P. Hwang, Y. Zhao and M. N. Robertson	2016	J. Viral Hepat.	23	10	789-97		https://doi.org/10.1111/jvh.1255225266289	Virologic resistance analysis from a phase 2 study of MK-5172 combined with pegylated interferon/ribavirin in treatment-naive patients with hepatitis C virus genotype 1 infection.	Howe et al.	A. Y. Howe, S. Black, S. Curry, S. W. Ludmerer, R. Liu, R. J. Barnard, W. Newhard, P. M. Hwang, D. Nickle, C. Gilbert, L. Caro, M. J. DiNubile and N. Mobashery	2014	Clin. Infect. Dis.	59	12	1657-65		https://doi.org/10.1093/cid/ciu696